Willow Review: Flat Pricing at Every Dose Is Genuinely Good — The Advertising History Is Genuinely Not

What Is Willow?

Willow — trading as Start Willow, operated by Willow Health Services, Inc. — is a telehealth company selling compounded GLP-1 medication direct to consumers. You complete an online health assessment, a US-licensed physician reviews it, and if approved a compounded preparation is shipped to your door monthly. It offers compounded semaglutide as a weekly injection at $299/mo, compounded tirzepatide as a weekly injection at $399/mo, and a distinctive compounded semaglutide sublingual tablet, also $299/mo, for people who will not inject.

Two things about the pricing are genuinely good. It is flat across every dose, so the price you sign up at is the price you pay at a maintenance dose — a real advantage in a market where headline rates routinely stop applying once you titrate. And plans are HSA/FSA eligible, which is not universal here. Included in the price are same-day prescription approval, free 2-day shipping, free follow-up consultations, 24/7 support, batch quality testing and optional anti-nausea medication.

Willow is also unusually clear about regulatory status. Its own product pages carry the statement that its formulations 'are not approved by the U.S. Food and Drug Administration (FDA) and have not undergone clinical trials to evaluate their safety, efficacy, or therapeutic equivalence to any FDA-approved medications.' That is a more complete and more honest disclosure than most compounded sellers offer.

The reason we still rate Willow below several cheaper competitors is its advertising record, which is documented rather than alleged and is set out in full below. It is the sort of history that should change how much weight you give a company's other claims about itself.

Medications Offered & Pricing

Prices are Willow's published rates as listed on 6 August 2026 and hold flat as your dose increases, which is the single most useful thing about the pricing. Everything Willow sells is compounded — there are no brand-name Ozempic, Wegovy, Mounjaro or Zepbound options here at any price. Compare $299/mo carefully against the market: several providers we have reviewed sell compounded semaglutide between $89 and $199/mo, so Willow is priced at the upper end of the compounded range while offering a product with the same regulatory status.

Brand-Name or Compounded?

Everything Willow offers is compounded and none of it is FDA-approved. To Willow's credit it says so plainly on its own product pages, including the important detail that its formulations 'have not undergone clinical trials to evaluate their safety, efficacy, or therapeutic equivalence to any FDA-approved medications.' Many compounded sellers bury or omit that second half.

The sublingual tablet deserves particular scrutiny. Semaglutide is a large peptide, and the FDA-approved oral form (Rybelsus) requires a specific absorption enhancer and strict dosing conditions to achieve meaningful bioavailability. A compounded sublingual tablet is a different proposition again, and there is no published clinical trial evidence establishing that it delivers comparable drug exposure to an approved injectable or oral product. If you are choosing tablets to avoid needles, understand that you are accepting materially more uncertainty about whether the medication is working as intended, not just a different format.

One technical finding from the NAD proceedings below is worth carrying into any compounded purchase: NAD noted that Willow's compounded versions differed from the approved products 'in active pharmaceutical ingredient, formulation, and method of administration.' A difference in active pharmaceutical ingredient — not merely formulation — is a substantive distinction, and it is exactly why evidence from trials of the branded drug cannot simply be transferred to a compounded one.

The Consultation Process

Eligibility

• •Eligibility is determined by a free online health assessment reviewed by a US-licensed physician. Willow does not publish a specific BMI threshold, and at least one public reviewer noted qualifying without being obese.
• •State availability is not published on the product pages we reviewed. Confirm your state is served before starting.
• •GLP-1 medicines are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and are not for use in pregnancy or while trying to conceive.
• •Caution and clinician judgement are required for anyone with a history of pancreatitis, gallbladder disease, severe gastrointestinal disease including gastroparesis, or diabetic retinopathy.
• •Common side effects are gastrointestinal — nausea, vomiting, diarrhoea, constipation and reflux — usually worst after a dose increase. Serious but less common risks include pancreatitis, gallbladder disease and dehydration-related kidney injury.
• •Anyone who wants a medication whose safety and efficacy have been established in clinical trials should use a provider offering FDA-approved products. Willow does not offer any.

Provider Involvement, Labs & Pharmacy

Shipping & Support Services

Free, discreet 2-day shipping is included in the plan price with monthly delivery. Some public reviewers report tracking visibility as a weak point, so confirm dispatch rather than assuming a refill is on its way.

• •Price stays flat as your dose increases
• •HSA/FSA eligible
• •Free 2-day discreet shipping included
• •Free follow-up consultations with the care team
• •24/7 customer support
• •Same-day prescription approval
• •Optional anti-nausea medication (generic ondansetron)
• •Sublingual tablet option for people who will not inject
• •Clear, complete FDA-status disclosure on product pages

Fees, Cancellation & Refunds

Insurance & HSA/FSA

Pros & Cons

Who Willow May Be Best For

• •People who will titrate to a high maintenance dose and want the price fixed from the start
• •Anyone paying with HSA or FSA funds, where the pre-tax saving materially closes the price gap
• •Patients who genuinely will not inject and understand the added uncertainty of a compounded sublingual product
• •People who value bundled follow-ups, fast approval and free shipping over the lowest headline price

Limitations

• •The advertising history is the reason this review is not more positive, and it deserves stating precisely rather than vaguely. On 4 December 2025, following a challenge by Novo Nordisk, the National Advertising Division found that Willow Health had not substantiated its express claims regarding health, weight loss, implied benefits, superiority or efficacy. NAD noted the studies Willow cited covered only Novo Nordisk's FDA-approved products, and were insufficient because Willow's compounded versions differed in active pharmaceutical ingredient, formulation and method of administration. Willow did not provide a statement agreeing to comply, so NAD referred it to the relevant state attorneys general and to the platforms carrying the advertising.
• •In fairness, that is not the end of the story. Willow returned to NAD after discussion with the FTC, NAD reopened the matter, and on 24 July 2026 Willow confirmed it had permanently discontinued all the challenged claims — including that its products were proven to support weight loss, delivered results comparable to FDA-approved semaglutide, and produced effective weight loss without diet or exercise. NAD treats those claims as discontinued for compliance purposes. The product pages we reviewed no longer carry them.
• •What you do with that is a judgement call. The claims are gone and the current pages are clean and appropriately disclaimed. But a company that used branded-drug trial data to sell a compounded product, declined to comply when told to stop, and only relented after a regulator referral and FTC involvement has told you something about how it weighs marketing against evidence. Apply that discount to everything else it says about itself.
• •On price alone, Willow is hard to justify. $299/mo for compounded semaglutide sits well above providers offering the same regulatory category for $89–$199. The flat-dose pricing and HSA/FSA eligibility genuinely narrow that gap — a $299 HSA-funded plan may cost you less after tax than a $199 cash plan — but you should run that calculation rather than assume it.

Alternatives to Consider

Frequently Asked Questions

Our Verdict

Willow has built a product with two features this market badly needs: a price that does not climb as you titrate, and HSA/FSA eligibility that quietly takes 20–35% off the real cost. Add free shipping, free follow-ups and same-day approval, and the package is coherent. Its FDA-status disclosure is also better than most — it states not just that the products are unapproved but that they have not been trialled for efficacy or therapeutic equivalence, which is the part competitors usually omit.

Against that sits a documented advertising record. NAD found Willow's compounded semaglutide claims unsubstantiated in December 2025, Willow declined to comply, and it was referred to state attorneys general and advertising platforms. The claims were permanently discontinued only in July 2026, after the company returned to NAD following FTC discussions. The pages are clean now and that correction counts for something — but the sequence tells you the company stopped because it was made to, not because it reconsidered.

We rate Willow 3.0 out of 5. The pricing architecture is good and the current disclosures are honest, but you are paying an upper-market price for a compounded product from a company with a regulator referral in its recent past, when CallonDoc sells the same category at $89/mo and CoreAge Rx at $99/mo. If the flat-dose pricing plus HSA funds genuinely make it cheapest for your situation, run that maths and it may be a reasonable buy. If not, there are better-priced providers with cleaner records.

This review is informational only and is not medical advice. Compounded GLP-1s are not FDA-approved and have not been shown in trials to be equivalent to approved medicines. Speak to a licensed clinician about whether treatment is appropriate for you before starting, changing or stopping any medication.